Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Tharani Sivakumaran"'
Autor:
Madhu Singh, Linda Mileshkin, Penelope Schofield, Bo Gao, Gary Richardson, Andrew Pattison, Rodney J Hicks, Niko Thio, Mark Warren, Colin Wood, Stephen B Fox, Anna DeFazio, Andrew Fellowes, Christopher Steer, David Bowtell, Nicholas Wilcken, Tharani Sivakumaran, Atara Posner, Dariush Etemadmoghadam, Krista Fisher, Samantha Webb, Christos S Karapetis, Ian M Collins, Narayan Karanth, Owen W J Prall, Richard William Tothill
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 1 (2023)
Background Cancer of unknown primary (CUP) is a heterogeneous group of metastatic cancers where a primary tissue of origin (TOO) is uncertain. Most patients with CUP have limited treatment options and poor survival outcomes. Immune checkpoint inhibit
Externí odkaz:
https://doaj.org/article/62a3f3bb406f4f688c1bd4d184af4202
Autor:
Atara Posner, Owen WJ Prall, Tharani Sivakumaran, Dariush Etemadamoghadam, Niko Thio, Andrew Pattison, Shiva Balachander, Krista Fisher, Samantha Webb, Colin Wood, Anna DeFazio, Nicholas Wilcken, Bo Gao, Christos S Karapetis, Madhu Singh, Ian M Collins, Gary Richardson, Christopher Steer, Mark Warren, Narayan Karanth, Gavin Wright, Scott Williams, Joshy George, Rodney J Hicks, Alex Boussioutas, Anthony J Gill, Benjamin J Solomon, Huiling Xu, Andrew Fellowes, Stephen B Fox, Penelope Schofield, David Bowtell, Linda Mileshkin, Richard W Tothill
Publikováno v:
The Journal of Pathology. 259:81-92
Cancer of unknown primary (CUP) is a syndrome defined by clinical absence of a primary cancer after standardised investigations. Gene expression profiling (GEP) and DNA sequencing have been used to predict primary tissue of origin (TOO) in CUP and fi
Autor:
Arielle van Mourik, Gina Tonkin-Hill, John O’Farrell, Shohei Waller, Lavinia Tan, Richard W. Tothill, David Bowtell, Stephen Fox, Andrew Fellowes, Clare Fedele, Penelope Schofield, Tharani Sivakumaran, Hui-Li Wong, Linda Mileshkin
Publikováno v:
British Journal of Cancer.
Background Diagnosis and management of cancers of unknown primary (CUP) remain challenging. This study examines the referral patterns, management and outcomes of patients referred to Australia’s first dedicated CUP clinic. Methods Retrospective med
Autor:
Atara Posner, Owen W.J. Prall, Tharani Sivakumaran, Dariush Etemadamoghadam, Niko Thio, Andrew Pattison, Shiva Balachander, Krista Fisher, Samantha Webb, Colin Wood, Anna DeFazio, Nicholas Wilcken, Bo Gao, Christos S Karapetis, Madhu Singh, Ian M Collins, Gary Richardson, Christopher Steer, Mark Warren, Narayan Karanth, Gavin Wright, Scott Williams, Joshy George, Rodney J Hicks, Alex Boussioutas, Anthony J Gill, Benjamin J. Solomon, Huiling Xu, Andrew Fellowes, Stephen B Fox, Penelope Schofield, David Bowtell, Linda Mileshkin, Richard W. Tothill
Cancer of unknown primary (CUP) constitutes a group of metastatic cancers in which standardized clinical investigations fail to identify a tissue of origin (TOO). Gene-expression profiling (GEP) has been used to resolve TOO, and DNA sequencing to ide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ea898e05b1fb367e20fa6da5f32b1279
https://doi.org/10.1101/2022.06.24.22276729
https://doi.org/10.1101/2022.06.24.22276729
Autor:
Tharani Sivakumaran, Michael Krasovitsky, Alison Freimund, Yeh Chen Lee, Kate Webber, Jane So, Christie Norris, Michael Friedlander, Linda Mileshkin, George Au-Yeung
Publikováno v:
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 32(7)
ObjectivesThe primary objective of this study was to describe treatment patterns after poly-ADP ribose polymerase (PARP) inhibitor in patients with epithelial ovarian cancer. Secondary objectives were to evaluate duration of response, time to first s
Autor:
Andreas Obermair, Peter Grant, Anna deFazio, Michael Friedlander, Linda Mileshkin, L Na, Penelope M. Webb, George Au-Yeung, Tharani Sivakumaran
Publikováno v:
Gynecologic Oncology. 158:47-53
To determine the impact of chemotherapy dose reductions and dose delays on progression-free survival (PFS) in women with ovarian cancer receiving first line chemotherapy in a real world prospective cohort study.Patients with newly diagnosed epithelia
Autor:
Atara Posner, Tharani Sivakumaran, Andrew Pattison, Dariush Etemadmoghadam, Niko Thio, Colin Wood, Krista Fisher, Samantha Webb, Anna DeFazio, Nicholas Wilcken, Bo Gao, Christos S Karapetis, Madhu Singh, Ian M Collins, Gary Richardson, Christopher Steer, Mark Warren, Narayan Karanth, Andrew Fellowes, Stephen B Fox, Rodney J Hicks, Penelope Schofield, David Bowtell, Owen W J Prall, Richard William Tothill, Linda Mileshkin
Publikováno v:
Journal for ImmunoTherapy of Cancer. 11:e005809
BackgroundCancer of unknown primary (CUP) is a heterogeneous group of metastatic cancers where a primary tissue of origin (TOO) is uncertain. Most patients with CUP have limited treatment options and poor survival outcomes. Immune checkpoint inhibito
Autor:
Tharani Sivakumaran, Anthony Cardin, Jason Callahan, Hui-Li Wong, Richard Tothill, Rodney Hicks, Linda R. Mileshkin
Publikováno v:
Journal of Clinical Oncology. 40:3062-3062
3062 Background: Cancer of unknown primary (CUP) represents a heterogeneous group of metastatic tumours where standardized diagnostic work-up fails to identify the tissue of origin (TOO). Small studies, to date mainly focused on cervical lymph node s
Autor:
Tharani Sivakumaran, Linda Mileshkin, Michael Friedlander, J So, M Krasovitsky, George Au-Yeung, K Webber, K Chen Lee, Alison Freimund, C Norris
Publikováno v:
Poster.
Introduction PARP inhibitors (PARPi) have changed the management landscape for patients with epithelial ovarian cancer (EOC). However, as with many targeted therapies, treatment resistance is common. The response to treatment post-PARPi has not been
Autor:
Penelope Schofield, Ian M. Collins, Tharani Sivakumaran, Madhu Sudan Singh, Christos S. Karapetis, Andrew Fellowes, Anna deFazio, Stephen B. Fox, Mark Andrew Warren, Richard W. Tothill, Alison Freimund, Gary Richardson, Bo Gao, Nicholas Wilcken, Cindy Bryant, Dariush Etemadmoghadam, Lisa Guccione, David D.L. Bowtell, Christopher Steer, Linda Mileshkin
Publikováno v:
Journal of Clinical Oncology. 37:3072-3072
3072 Background: Cancer of unknown primary (CUP) has a poor prognosis with a median survival of less than 12 months. SUPER is a prospective cohort study designed to create a national biobank of patients (pts) with no confirmed primary site following